Trial · NCT03989349
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Investigator's Global Assessment (IGA) Success at Week 16: Intent-To-Treat (ITT) Population | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 37.7 | percentage of participants | ||
| Percentage of Participants With Investigator's Global Assessment (IGA) Success at Week 16: Intent-To-Treat (ITT) Population | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 26.0 | percentage of participants | ||
| Percentage of Participants With Investigator's Global Assessment (IGA) Success at Week 16: Severe Pruritus Population | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 36.7 | percentage of participants | ||
| Percentage of Participants With Investigator's Global Assessment (IGA) Success at Week 16: Severe Pruritus Population | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 22.0 | percentage of participants | ||
| Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at Week 16: ITT Population | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 42.1 | percentage of participants | ||
| Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at Week 16: ITT Population | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 30.2 | percentage of participants | ||
| Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at Week 16: Severe Pruritus Population | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 41.1 | percentage of participants | ||
| Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at Week 16: Severe Pruritus Population | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 25.0 | percentage of participants | ||
| Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: ITT Population | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 41.0 | percentage of participants | ||
| Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: ITT Population | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 18.1 | percentage of participants | ||
| Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: Severe Pruritus Population | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 48.4 | percentage of participants | ||
| Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: Severe Pruritus Population | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 21.3 | percentage of participants | ||
| Percentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: ITT Population | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 28.4 | percentage of participants | ||
| Percentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: ITT Population | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 11.3 | percentage of participants | ||
| Percentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: Severe Pruritus Population | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 26.9 | percentage of participants | ||
| Percentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: Severe Pruritus Population | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 8.5 | percentage of participants | ||
| Percentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: ITT Population | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 33.5 | percentage of participants | ||
| Percentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: ITT Population | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 16.2 | percentage of participants | ||
| Percentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: Severe Pruritus Population | Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg | 42.7 | percentage of participants | ||
| Percentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: Severe Pruritus Population | Initial Treatment Period (Baseline - Week 16 Predose): Placebo | 20.7 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03989349/results